112 related articles for article (PubMed ID: 26839699)
21. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
Castagneto B; Botta M; Aitini E; Spigno F; Degiovanni D; Alabiso O; Serra M; Muzio A; Carbone R; Buosi R; Galbusera V; Piccolini E; Giaretto L; Rebella L; Mencoboni M
Ann Oncol; 2008 Feb; 19(2):370-3. PubMed ID: 18156144
[TBL] [Abstract][Full Text] [Related]
23. Pemetrexed in malignant pleural mesothelioma.
Gatzemeier U
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
[TBL] [Abstract][Full Text] [Related]
24. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
Pasello G; Urso L; Silic-Benussi M; Schiavon M; Cavallari I; Marulli G; Nannini N; Rea F; Ciminale V; Favaretto A
J Thorac Oncol; 2014 Jul; 9(7):1008-1017. PubMed ID: 24922007
[TBL] [Abstract][Full Text] [Related]
25. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
Razak AR; Chatten KJ; Hughes AN
Lung Cancer; 2008 May; 60(2):294-7. PubMed ID: 17919769
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
[TBL] [Abstract][Full Text] [Related]
27. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM).
Pasello G; Marulli G; Polo V; Breda C; Bonanno L; Loreggian L; Rea F; Favaretto A
Anticancer Res; 2012 Dec; 32(12):5393-9. PubMed ID: 23225442
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of nanoparticle albumin-bound paclitaxel plus carboplatin in non-small lung cancer patients with malignant pleural effusion.
Koyama N; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Aoshiba K; Nakamura H
Neoplasma; 2018; 65(1):132-139. PubMed ID: 29322797
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed for diffuse malignant pleural mesothelioma.
Manegold C; Aisner J
Semin Oncol; 2002 Apr; 29(2 Suppl 5):30-5. PubMed ID: 12023790
[TBL] [Abstract][Full Text] [Related]
30. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
[TBL] [Abstract][Full Text] [Related]
31. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
32. Second-line treatment for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin.
Ryad AY; Mostafa E; Salem DA; Al-Adwy ER; Margerges M
J Egypt Natl Canc Inst; 2007 Mar; 19(1):61-70. PubMed ID: 18839036
[TBL] [Abstract][Full Text] [Related]
34. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Tsumori T; Kawase I
Anticancer Res; 2012 Feb; 32(2):609-13. PubMed ID: 22287752
[TBL] [Abstract][Full Text] [Related]
35. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.
Sørensen JB; Sundstrøm S; Perell K; Thielsen AK
J Thorac Oncol; 2007 Feb; 2(2):147-52. PubMed ID: 17410031
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
[TBL] [Abstract][Full Text] [Related]
37. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods B; Paracha N; Scott DA; Thatcher N
Lung Cancer; 2012 Feb; 75(2):261-7. PubMed ID: 21937141
[TBL] [Abstract][Full Text] [Related]
38. Overview on ongoing or planned clinical trials in Europe.
Favaretto A
Lung Cancer; 2005 Jul; 49 Suppl 1():S117-21. PubMed ID: 15950791
[TBL] [Abstract][Full Text] [Related]
39. Current concepts in chemotherapy for malignant pleural mesothelioma.
Sørensen JB
Clin Respir J; 2008 Apr; 2(2):74-9. PubMed ID: 20298310
[TBL] [Abstract][Full Text] [Related]
40. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
